CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
LE 7X01
Phase 2 small_molecule active
Quick answer
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib for primary immunodeficiency is a Phase 2 program (small_molecule) at Pharming Technologies B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharming Technologies B.V.
- Indication
- primary immunodeficiency
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active